Of note, Hes and Nar anti-MM effects were not antagonized by co-culture with patient-derived BMSCs, underscoring the potential ability of these two compounds to overcome the protective effects of the bone marrow microenvironment. The gene discussed is CPSF4; the disease is Miyoshi myopathy.